Regional variation in medication following coronary events in Germany

International Journal of Cardiology

Volumn 102, Issue 1, 2005, Pages 47-53

  Müller Nordhorn, Jacqueline ^a   Kulig, Michael ^a   Binting, Sylvia ^a   Völler, Heinz ^b   Krobot, Karl J ^c   Willich, Stefan N ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Klinik am See   (Germany)

^c MSD Sharp and Dohme GmbH   (Germany)

Author keywords

Coronary disease; Germany; Medication; Regional variation; Rehabilitation

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DEMOGRAPHY; FEMALE; FOLLOW UP; GERMAN DEMOCRATIC REPUBLIC; GERMAN FEDERAL REPUBLIC; HEART INFARCTION; HEART REHABILITATION; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT PARTICIPATION; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; RISK FACTOR; TRANSLUMINAL CORONARY ANGIOPLASTY;

ADRENERGIC BETA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTILIPEMIC AGENTS; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; GERMANY, EAST; GERMANY, WEST; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PRESCRIPTIONS, DRUG; PROSPECTIVE STUDIES; SMALL-AREA ANALYSIS; SURVIVAL RATE;

EID: 20444492022     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2004.03.074     Document Type: Article

References (38)

1. K. Uemara, and Z. Pisa Trends in cardiovascular disease mortality in industrialized countries since 1950 World Health Stat. Q. 41 1988 155 178
2. S. Sans, H. Kesteloot, and D. Kroumhout The burden of cardiovascular diseases mortality in Europe. Task force of the European Society of Cardiology on cardiovascular mortality and morbidity statistics in Europe Eur. Heart J. 18 1997 1231 1248
3. J. Müller-Nordhorn, K. Rossnagel, W. Mey, and S.N. Willich Regional variation and time trends in mortality from ischaemic heart disease: East and West Germany 10 years after reunification J. Epidemiol. Community Health 58 2004 481 485
4. Statistisches Bundesamt Statistisches Jahrbuch für die Bundesrepublik Deutschland 2001 2001 Metzler-Poeschel Stuttgart
5. M. Bobak, and M. Marmot East-west mortality divide and its potential explanations: proposed research agenda BMJ 312 1996 421 425
6. E. Nolte, V. Shkolnikov, and M. McKee Changing mortality patterns in East and West Germany and Poland: I. Long term trends (1960-1997) J. Epidemiol. Community Health 54 2000 890 899
7. H. Tunstall-Pedoe, K. Kuulasmaa, M. Mähönen, H. Tolonen, E. Ruokokoski, and P. Amouyel Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations Lancet 353 1999 1547 1557
8. H. Tunstall-Pedoe, D. Vanuzzo, M. Hobbs, M. Mahonen, Z. Cepaitis, and K. Kuulasmaa Estimation of contribution of changes in coronary care to improving survival, event rates, and coronary heart disease mortality across the WHO MONICA Project populations Lancet 355 2000 688 700
9. H. Pardell, E. Roure, W. Drygas, E. Morava, E. Nussel, and P. Puska East-west differences in reported preventive practices Eur. J. Public Health 11 2001 393 396
10. Antiplatelet Trialist's Collaboration Collaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients BMJ 308 1994 81 106
11. S. Yusuf, R. Peto, J. Lewis, R. Collins, and P. Sleight Beta-blockade during and after myocardial infarction, an overview of the randomized trials Prog. Cardiovasc. Dis. 27 1985 335 371
12. F.M. Sacks, M.A. Pfeffer, L.A. Moye, J.L. Rouleau, J.D. Rutherford, and T.G. Cole The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N. Engl. J. Med. 335 1996 1001 1009
13. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N. Engl. J. Med. 339 1998 1349 1357
14. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
15. M.D. Flather, S. Yusuf, L. Kober, M. Pfeffer, A. Hall, and G. Murray Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group Lancet 355 2000 1575 1581
16. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators N. Engl. J. Med. 342 2000 145 153
17. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention Eur. Heart J. 19 1998 1434 1503
18. EUROASPIRE I and II Group Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries Lancet 357 2001 995 1001
19. H. Voller, H. Hahmann, H. Gohlke, G. Klein, B. Rombeck, and S. Binting Effects of inpatient rehabilitation on cardiovascular risk factors in patients with coronary heart disease. PIN-Study Group Dtsch. Med. Wochenschr. 124 1999 817 823
20. S.N. Willich PIN Study Group Cardiac risk factors, medication, and recurrent clinical events after acute coronary disease Eur. Heart J. 22 2001 307 313
21. D. Hosmer, and S. Lemeshow Applied logistic regression 2nd ed. 2000 Wiley New York
22. G.T. O'Connor, H.B. Quinton, N.D. Traven, L.D. Ramunno, T.A. Dodds, and T.A. Marciniak Geographic variation in the treatment of acute myocardial infarction. The Cooperative Cardiovascular Project JAMA 281 1999 627 633
23. L. Pilote, R.M. Califf, S. Sapp, D.P. Miller, D.B. Mark, and W.D. Weaver Regional variation across the United States in the management of acute myocardial infarction N. Engl. J. Med. 333 1995 565 572
24. B.M. Massie, J.G. Cleland, P.W. Armstrong, M. Packer, P.A. Poole-Wilson, and R. Lars Regional differences in the characteristics and treatment of patients participating in an international heart failure trial J. Card. Fail. 4 1998 3 8
25. R.G.J. Gibbs, R. Newson, R. Lawrenson, R.M. Greenhalgh, and A.H. Davies Diagnosis and initial management of stroke and transient ischaemic attack across UK Health Regions from 1992 to 1996. Experience from a National Primary Care Database Stroke 32 2001 1085 1090
26. M. Thamm Blood pressure in Germany-update review of state and trends Gesundheitswesen 61 suppl. 2 1999 S90 S93
27. H. Knopf, and H.U. Melchart Subjective statements on the daily intake of drugs from selected drug groups Gesundheitswesen 61 suppl. 2 1999 S151 S157
28. Zentralinstitut für die kassenärztliche Vereinigung in der Bundesrepublik Deutschland. Gesundheitszustand und ambulante medizinische Versorgung der Bevölkerung im Ost-West-Vergleich Publikationsreihe, Wissenschaftliche Reihe, Band vol. 56 2000 Deutscher Ärzte-Verlag Köln
29. B. Häussler, J. Bentz, and H.D. Nolting Arzneimittelverbrauch und Morbiditätsunterschiede A. Laukant Arzneimittelverbrauch in Ost- und Westdeutschland 1998 Novartis Pharma Nürnberg 73 96
30. K.O. Haustein Drug-prescription in the five new Federal Lands-a comparison with the prescription of the old Federal Lands of Germany Int. J. Clin. Pharmacol. Ther. Toxicol. 31 1993 399 403
31. S. Teich, and L. Eckensberger Informelle Institutionen und Transformation-eine kritische Würdigung der Ansätze der Neuen Institutionenökonomie P. Oberender Theorie und Praxis der Transformation von Wirtschaftssystemen 1998 Verlag P.C.O Bayreuth 77 92
32. U. Schwabe, and D. Paffrath Arzneiverordnungs-Report 2001 (Hrsg.) 2001 Springer-Verlag Berlin, Heidelberg
33. P. Kotler, and F. Bliemel Marketingstrategien für globale Märkte P. Kotler F. Bliemel Marketing-Management 1995 Schaeffer-Poeschel Stuttgart 619 659
34. K.L. Woods, D. Ketley, A. Lowy, A. Agusti, C. Hagn, and R. Kala Beta-blockers and antithrombotic treatment for secondary prevention after acute myocardial infarction Eur. Heart J. 19 1998 74 79
35. G.C. Fonarow, W.J. French, L.S. Parsons, H. Sun, and J.A. Malmgren Use of lipid-lowering medications at discharge in patients with acute myocardial infarction Circulation 103 2001 38 44
36. C.A. Sueta, M.W. Massing, M. Chowdhury, D.P. Biggs, and R.J. Simpson Jr. Undertreatment of hyperlipidemia in patients with coronary heart disease and heart failure J. Card. Fail. 9 2003 36 41
37. K.E. Bennett, D. Williams, and J. Feely Inequalities in prescribing of secondary preventative therapy for ischaemic heart disease in Ireland Ir. Med. J. 95 2002 169 172
38. H.V. Barron, A.D. Michaels, C. Maynard, and N.R. Every Use of angiotensin-converting enzyme inhibitors at discharge in patients with acute myocardial infarction in the United States: data from the National Registry of Myocardial Infarction 2 J. Am. Coll. Cardiol. 32 1998 360 367